MLICM
AKRO

Metropolitan Life Insurance Company (MetLife)’s Akero Therapeutics AKRO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,242
Closed -$81.9K – 84
2024
Q1 		$81.9K Buy
3,242
+263
+9% +$6.32K ﹤0.01% 1160
2023
Q4 		$69.6K Hold
2,979
– – ﹤0.01% 1273
2023
Q3 		$151K Buy
2,979
+525
+21% +$24.4K 0.01% 810
2023
Q2 		$115K Buy
2,454
+473
+24% +$21.7K 0.01% 951
2023
Q1 		$75.8K Sell
1,981
-175
-8% -$7.8K ﹤0.01% 1156
2022
Q4 		$118K Buy
2,156
+380
+21% +$16.3K 0.01% 967
2022
Q3 		$60.5K Hold
1,776
– – ﹤0.01% 1326
2022
Q2 		$16.8K Hold
1,776
– – ﹤0.01% 2124
2022
Q1 		$25.2K Sell
1,776
-5,750
-76% -$101K ﹤0.01% 1982
2021
Q4 		$159K Hold
7,526
– – ﹤0.01% 2183
2021
Q3 		$168K Hold
7,526
– – ﹤0.01% 2205
2021
Q2 		$187K Buy
7,526
+3,666
+95% +$103K ﹤0.01% 2196
2021
Q1 		$112K Hold
3,860
– – ﹤0.01% 2375
2020
Q4 		$99.6K Hold
3,860
– – ﹤0.01% 2361
2020
Q3 		$119K Hold
3,860
– – ﹤0.01% 2117
2020
Q2 		$96.2K Buy
+3,860
New +$88.2K ﹤0.01% 2273

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s AKRO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 3,242 shares — an estimated $81.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in AKRO in Q2 2020 and held it in 16 quarters. The position peaked at $187K in Q2 2021. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,242 Akero Therapeutics shares in Q2 2024, an estimated $81.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Akero Therapeutics in Q2 2020 and held it in 16 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Akero Therapeutics position peaked at $187K in Q2 2021.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.